Cardiology - Reviews
Early Access
Magnetic resonance imaging evaluation of the effects of myosin inhibitors (mavacamten and aficamten) in hypertrophic cardiomyopathy: a systematic review and case report
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: 5 December 2025
285
Views
296
Downloads
Authors
Hypertrophic cardiomyopathy (HCM) is a common inherited cardiac disorder, affecting approximately 1 in 250 individuals. It is defined by unexplained left ventricular (LV) hypertrophy in the absence of other identifiable cardiac or systemic causes. The clinical presentation is highly variable, ranging from asymptomatic individuals to those with complications such as sudden cardiac death, heart failure, and atrial fibrillation. Multimodal and longitudinal imaging is essential in HCM management. Among these, cardiac magnetic resonance (CMR) provides superior tissue characterization and accurate assessment of myocardial hypertrophy and fibrosis. CMR allows quantification of fibrosis through late gadolinium enhancement and T1 mapping, both critical for risk stratification and prognostic evaluation. Recently, cardiac myosin inhibitors (CMIs)—mavacamten and aficamten—have shown unprecedented potential in altering disease progression by reducing myocardial hypertrophy, hypercontractility, and LV outflow tract obstruction. This systematic review, prompted by a clinical case comparing baseline and 13-month follow-up CMR findings after mavacamten therapy in a female patient with HCM, aims to evaluate the impact of CMIs on CMR-derived parameters. Following a comprehensive PRISMA-guided search, three randomized controlled trials were included. Results demonstrated consistent reductions in LV mass, maximum LV wall thickness, and left atrial volume index. Two studies also reported significant reductions in absolute myocyte mass index, and one found a decrease in native T1 with aficamten. These findings highlight the value of CMR in unveiling the real effects of CMIs and reinforce the need for large-scale studies to confirm their long-term benefits in HCM management.
Downloads
Download data is not yet available.
Citations
Marian AJ. Molecular genetic basis of hypertrophic cardiomyopathy. Circ Res 2021;128:1533-53. DOI: https://doi.org/10.1161/CIRCRESAHA.121.318346
Ommen SR, Ho CY, Asif IM, et al. 2024 AHA/ACC/AMSSM/HRS/PACES/SCMR guideline for the management of hypertrophic cardiomyopathy: a report of the American Heart Association/American College of Cardiology Joint Committee on clinical practice guidelines. Circulation 2024;149:e1239-311. DOI: https://doi.org/10.1161/CIR.0000000000001250
Ommen SR, Semsarian C. Hypertrophic cardiomyopathy: a practical approach to guideline directed management. Lancet 2021;398:2102-8. DOI: https://doi.org/10.1016/S0140-6736(21)01205-8
Maron BJ. Clinical course and management of hypertrophic cardiomyopathy. N Engl J Med 2018;379:655-68. DOI: https://doi.org/10.1056/NEJMra1710575
Maron BJ, Rowin EJ, Casey SA, Maron MS. How hypertrophic cardiomyopathy became a contemporary treatable genetic disease with low mortality: shaped by 50 years of clinical research and practice. JAMA Cardiol 2016;1:98-105. DOI: https://doi.org/10.1001/jamacardio.2015.0354
Maron MS, Maron BJ, Harrigan C, et al. Hypertrophic cardiomyopathy phenotype revisited after 50 years with cardiovascular magnetic resonance. J Am Coll Cardiol 2009;54:220-8. DOI: https://doi.org/10.1016/j.jacc.2009.05.006
Abraham MR, Abraham TP. Role of imaging in the diagnosis, evaluation, and management of hypertrophic cardiomyopathy. Am J Cardiol 2024;212S:S14-32. DOI: https://doi.org/10.1016/j.amjcard.2023.10.081
Altibi A, Alani A, Zhao YZ, Masri A. Baseline and longitudinal imaging of hypertrophic cardiomyopathy in the era of emerging therapeutics. Curr Cardiol Rep 2023;25:583-95. DOI: https://doi.org/10.1007/s11886-023-01883-w
Dong T, Gilliland Y, Kramer CM, et al. Multimodality imaging of hypertrophic cardiomyopathy. Prog Cardiovasc Dis 2023;80:14-24. DOI: https://doi.org/10.1016/j.pcad.2023.08.004
Tower-Rader A, Kramer CM, Neubauer S, et al. Multimodality imaging in hypertrophic cardiomyopathy for risk stratification. Circ Cardiovasc Imaging 2020;13:e009026. DOI: https://doi.org/10.1161/CIRCIMAGING.119.009026
Anghel L, Stătescu C, Șerban IL, et al. The advantages of new multimodality imaging in choosing the optimal management strategy for patients with hypertrophic cardiomyopathy. Diagnostics 2020;10:719. DOI: https://doi.org/10.3390/diagnostics10090719
Vucicevic D, Lester SJ, Appleton CP, et al. The incremental value of magnetic resonance imaging for identification of apical pouch in patients with apical variant of hypertrophic cardiomyopathy. Echocardiography 2016;33:572-8. DOI: https://doi.org/10.1111/echo.13118
Maron MS, Finley JJ, Bos JM, et al. Prevalence, clinical significance, and natural history of left ventricular apical aneurysms in hypertrophic cardiomyopathy. Circulation 2008;118:1541-9. DOI: https://doi.org/10.1161/CIRCULATIONAHA.108.781401
Aquaro GD, De Gori C, Faggioni L, et al. Diagnostic and prognostic role of late gadolinium enhancement in cardiomyopathies. Eur Heart J Suppl 2023;25:C130-6. DOI: https://doi.org/10.1093/eurheartjsupp/suad015
Kosuge H, Hachiya S, Fujita Y, et al. Potential of non-contrast stress T1 mapping for the assessment of myocardial injury in hypertrophic cardiomyopathy. J Cardiovasc Magn Reson 2023;25:53. DOI: https://doi.org/10.1186/s12968-023-00966-5
Weng Z, Yao J, Chan RH, et al. Prognostic value of LGE-CMR in HCM: a meta-analysis. JACC Cardiovasc Imaging 2016;9:1392-402. DOI: https://doi.org/10.1016/j.jcmg.2016.02.031
Adabag AS, Maron BJ, Appelbaum E, et al. Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. J Am Coll Cardiol 2008;51:1369-74. DOI: https://doi.org/10.1016/j.jacc.2007.11.071
Bruder O, Wagner A, Jensen CJ, et al. Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2010;56:875-87. DOI: https://doi.org/10.1016/j.jacc.2010.05.007
Raphael CE, Mitchell F, Kanaganayagam GS, et al. Cardiovascular magnetic resonance predictors of heart failure in hypertrophic cardiomyopathy: the role of myocardial replacement fibrosis and the microcirculation. J Cardiovasc Magn Reson 2021;23:26. DOI: https://doi.org/10.1186/s12968-021-00720-9
Olivotto I, Maron BJ, Appelbaum E, et al. Spectrum and clinical significance of systolic function and myocardial fibrosis assessed by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. Am J Cardiol 2010;106:261-7. DOI: https://doi.org/10.1016/j.amjcard.2010.03.020
Mewton N, Liu CY, Croisille P, et al. Assessment of myocardial fibrosis with cardiovascular magnetic resonance. J Am Coll Cardiol 2011;57:891-903. DOI: https://doi.org/10.1016/j.jacc.2010.11.013
Li Y, Liu X, Yang F, et al. Prognostic value of myocardial extracellular volume fraction evaluation based on cardiac magnetic resonance T1 mapping with T1 long and short in hypertrophic cardiomyopathy. Eur Radiol 2021;31:4557-67. DOI: https://doi.org/10.1007/s00330-020-07650-7
Nagueh SF, Phelan D, Abraham T, et al. Recommendations for multimodality cardiovascular imaging of patients with hypertrophic cardiomyopathy: an update from the American Society of Echocardiography, in collaboration with the American Society of Nuclear Cardiology, the Society for Cardiovascular Magnetic Resonance, and the Society of Cardiovascular Computed Tomography. J Am Soc Echocardiogr 2022;35:533-69. DOI: https://doi.org/10.1016/j.echo.2022.03.012
Ostrominski JW, Guo R, Elliott PM, Ho CY. Cardiac myosin inhibitors for managing obstructive hypertrophic cardiomyopathy: JACC: Heart Failure state-of-the-art review. JACC Heart Fail 2023;11:735-48. DOI: https://doi.org/10.1016/j.jchf.2023.04.018
Green EM, Wakimoto H, Anderson RL, et al. A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice. Science 2016;351:617-21. DOI: https://doi.org/10.1126/science.aad3456
Heitner SB, Jacoby D, Lester SJ, et al. Mavacamten treatment for obstructive hypertrophic cardiomyopathy: a clinical trial. Ann Intern Med 2019;170:741-8. DOI: https://doi.org/10.7326/M18-3016
Braunwald E, Saberi S, Abraham TP, et al. Mavacamten: a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy. Eur Heart J 2023;44:4622-33. DOI: https://doi.org/10.1093/eurheartj/ehad637
Keam SJ. Mavacamten: first approval. Drugs 2022;82:1127-35. DOI: https://doi.org/10.1007/s40265-022-01739-7
Page MJ, Moher D, Bossuyt PM, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ 2021;372:n160. DOI: https://doi.org/10.1136/bmj.n160
Lefebvre C, Glanville J, Briscoe S, et al. 2024. In: Cochrane handbook for systematic reviews of interventions [Internet]. Cochrane. Version 6.5. Available from: www.training.cochrane.org/handbook.
Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:I4898. DOI: https://doi.org/10.1136/bmj.l4898
Current version of RoB 2. Risk of bias tools. Available from: https://www.riskofbias.info/welcome/rob-2-0-tool/current-version-of-rob-2.
Masri A, Cardoso RN, Abraham TP, et al. Effect of aficamten on cardiac structure and function in obstructive hypertrophic cardiomyopathy SEQUOIA-HCM CMR substudy. J Am Coll Cardiol 2024;84:1806-17. DOI: https://doi.org/10.1016/j.jacc.2024.08.015
Saberi S, Cardim N, Yamani M, et al. Mavacamten favorably impacts cardiac structure in obstructive hypertrophic cardiomyopathy EXPLORER-HCM cardiac magnetic resonance substudy analysis. Circulation 2021;143:606-8. DOI: https://doi.org/10.1161/CIRCULATIONAHA.120.052359
Tian Z, Li L, Li X, et al. Effect of mavacamten on Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy: the EXPLORER-CN randomized clinical trial. JAMA Cardiol 2023;8:957‐65. DOI: https://doi.org/10.1001/jamacardio.2023.3030
Olivotto I, Oreziak A, Barriales-Villa R, et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2020;396:759-69. DOI: https://doi.org/10.1016/S0140-6736(20)31792-X
Tian Z, Wang F, Jin W, et al. Study design and rationale of EXPLORER-CN: a phase III, randomised, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of mavacamten in Chinese adults with symptomatic obstructive hypertrophic cardiomyopathy. BMJ Open 2023;13:e071473. DOI: https://doi.org/10.1136/bmjopen-2022-071473
Maron MS, Masri A, Nassif ME, et al. Aficamten for symptomatic obstructive hypertrophic cardiomyopathy. N Engl J Med 2024;390:1849-61. DOI: https://doi.org/10.1056/NEJMoa2401424
Ho CY, Olivotto I, Jacoby D, et al. Study design and rationale of EXPLORER-HCM: evaluation of mavacamten in adults with symptomatic obstructive hypertrophic cardiomyopathy. Circ Heart Fail 2020;13:e006853. DOI: https://doi.org/10.1161/CIRCHEARTFAILURE.120.006853
Debonnaire P, Joyce E, Hiemstra Y, et al. Left atrial size and function in hypertrophic cardiomyopathy patients and risk of new-onset atrial fibrillation. Circ Arrhythm Electrophysiol 2017;10:e004622. DOI: https://doi.org/10.1161/CIRCEP.116.004052
Yang WI, Shim CY, Kim YJ, et al. Left atrial volume index: a predictor of adverse outcome in patients with hypertrophic cardiomyopathy. J Am Soc Echocardiogr 2009;22:1338-43. DOI: https://doi.org/10.1016/j.echo.2009.09.016
Buckley BJR, Harrison SL, Gupta D, et al. Atrial fibrillation in patients with cardiomyopathy: prevalence and clinical outcomes from real-world data. J Am Heart Assoc 2021;10:e021970. DOI: https://doi.org/10.1161/JAHA.121.021970
Corriveau S, Heydari B, Garceau P. Does disopyramide still have a place in the management of obstructive hypertrophic cardiomyopathy? CJC Open 2024;6:811-7. DOI: https://doi.org/10.1016/j.cjco.2024.03.006
Dybro AM, Rasmussen TB, Nielsen RR, et al. Randomized trial of metoprolol in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 2021;78:2505-17. DOI: https://doi.org/10.1016/j.jacc.2021.07.065
Patel N, Shetty NS, Gaonkar M, et al. Procedural volume and outcomes after septal reduction therapies in hypertrophic obstructive cardiomyopathy. J Am Heart Assoc 2024;13:e036387. DOI: https://doi.org/10.1161/JAHA.124.036387
Xu J, Zhuang B, Sirajuddin A, et al. MRI T1 mapping in hypertrophic cardiomyopathy: evaluation in patients without late gadolinium enhancement and hemodynamic obstruction. Radiology 2020;294:275-86. DOI: https://doi.org/10.1148/radiol.2019190651
Hinojar R, Varma N, Child N, et al. T1 mapping in discrimination of hypertrophic phenotypes: hypertensive heart disease and hypertrophic cardiomyopathy: findings from the international T1 multicenter cardiovascular magnetic resonance study. Circ Cardiovasc Imaging 2015;8:e003317. DOI: https://doi.org/10.1161/CIRCIMAGING.115.003285
Smiseth OA, Fernandes JF, Lamata P. The challenge of understanding heart failure with supernormal left ventricular ejection fraction: time for building the patient's 'digital twin'. Eur Heart J Cardiovasc Imaging 2023;24:301-3. DOI: https://doi.org/10.1093/ehjci/jeac268
Shah S, Segar MW, Kondamudi N, et al. Supranormal left ventricular ejection fraction, stroke volume, and cardiovascular risk: gindings from population-based cohort dtudies. JACC Heart Fail 2022;10:583-94. DOI: https://doi.org/10.1016/j.jchf.2022.05.007
Chang HC, Tseng CH, Huang WM, et al. Supranormal left ventricular ejection fraction, concentric remodeling, and long-term survival. JACC Asia 2024;4:928-37. DOI: https://doi.org/10.1016/j.jacasi.2024.08.020
Ho CY, Mealiffe ME, Bach RG, et al. Evaluation of mavacamten in symptomatic patients with nonobstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 2020;75:2649-60. DOI: https://doi.org/10.1016/j.jacc.2020.03.064
Masri A, Sherrid MV, Abraham TP, et al. Efficacy and safety of sficamten in symptomatic nonobstructive hypertrophic cardiomyopathy: results from the REDWOOD-HCM trial, cohort 4. J Card Fail 2024;30:1439-48. DOI: https://doi.org/10.1016/j.cardfail.2024.02.020
Wang A, Lakdawala NK, Abraham TP, et al. Association between age or duration of diagnosis in obstructive hypertrophic cardiomyopathy and response to mavacamten treatment: exploratory analysis of the EXPLORER-HCM trial. J Card Fail 2025;31:901-11. DOI: https://doi.org/10.1016/j.cardfail.2024.10.449
How to Cite
“Magnetic Resonance Imaging Evaluation of the Effects of Myosin Inhibitors (mavacamten and Aficamten) in Hypertrophic Cardiomyopathy: A Systematic Review and Case Report”. 2025. Monaldi Archives for Chest Disease, December. https://doi.org/10.4081/monaldi.2025.3506.
Copyright (c) 2025 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.